Drug resistance of Mycobacterium tuberculosis and susceptibility of multidrug-resistant strains to linezolid in 5cities in Hebei Province
10.3969/j.issn.1671-9638.2018.03.002
- VernacularTitle:河北省五市结核分枝杆菌耐药情况及耐多药菌株对利奈唑胺的敏感性
- Author:
Yi XU
1
;
Zhi ZHANG
;
Yue-Yang TIAN
;
Ya-Nan LI
;
Hui-Xia GAO
Author Information
1. 石家庄市第五医院
- Keywords:
tuberculosis;
Mycobacterium tuberculosis;
linezolid;
multidrug resistance;
in vitro antimicrobial susceptibility
- From:
Chinese Journal of Infection Control
2018;17(3):191-195
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the drug resistance of Mycobacterium tuberculosis(MTB)and susceptibility of multidrug-resistant MTB(MDR-MTB)to linezolid in Hebei Province, so as to guiding clinical treatment of MDR tuberculosis.Methods The isolated strains and clinical information of patients with tuberculosis in 6 hospitals of 5 cities in Hebei Province between January and December 2016 were collected, susceptibility of MTB to antituberculous drugs isoniazid(INH), rifampicin(RFP), streptomycin(SM), ethambutol(EMB), ofloxacin(OFX), and kanamycin(KM)were detected, 100 strains of MDR-MTB were selected by stratified random sampling method, susceptibility to linezolid was detected.Results Drug resistance rate and MDR rate of the initially treated cases were 26.6%(200/753)and 13.5%(102/753)respectively, drug resistance rate and MDR rate of the retreatment cases were 59.7%(132/221)and 53.4(118/221)respectively, drug resistance rate and MDR rate of the retreatment cases were both statistically higher than initially treated cases(χ2=83.7, P<0.01;χ2=93.5, P<0.01).Resistance rates of MTB to first-line antituberculous drugs INH, RFP, SM, and EMB were 25.8%, 23.7%, 16.7%, and 7.1% respectively, to second-line antituberculous drugs OFX and KM were 4.7%(37/782)and 4.0%(31/782)respectively; susceptibility of MDR-MTB to linezolid was 80.8% (59/73).Conclusion Drug resistance rate and MDR rate of the retreated tuberculosis patients are higher than initially treated patients, linezolid has good in vitro antimicrobial activity against MDR-MTB.